MINT-ABACAVIR TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

ABACAVIR (ABACAVIR SULFATE)

Sẵn có từ:

MINT PHARMACEUTICALS INC

Mã ATC:

J05AF06

INN (Tên quốc tế):

ABACAVIR

Liều dùng:

300MG

Dạng dược phẩm:

TABLET

Thành phần:

ABACAVIR (ABACAVIR SULFATE) 300MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

60

Loại thuốc theo toa:

Prescription

Khu trị liệu:

NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0137623001; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2018-09-20

Đặc tính sản phẩm

_ _
_Page 1 of 42_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MINT-ABACAVIR
Abacavir Tablets
Tablets, 300 mg abacavir (as abacavir sulfate), Oral
USP
Antiretroviral Agent
Mint Pharmaceuticals Inc.
6575 Davand Drive,
Mississauga, Ontario
L5T 2M3
Date of Initial Authorization:
September 18, 2018
Date of Revision:
November 18, 2021
Submission Control No: 253731
_ _
_Page 2 of 42_
RECENT MAJOR LABEL CHANGES
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
11/2021
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
11/2021
7 WARNINGS AND PRECAUTIONS, General
11/2021
7 WARNINGS AND PRECAUTIONS, Hypersensitivity Reactions
11/2021
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 4
1. INDICATIONS
.........................................................................................................................
4
1.1
Pediatrics.......................................................................................................................
4
1.2
Geriatrics.......................................................................................................................
4
2. CONTRAINDICATIONS
........................................................................................................
4
3. SERIOUS WARNINGS AND PRECAUTIONS BOX
.......................................................... 5
4. DOSAGE AND ADMINISTRATION
....................................................................................
5
4.1 Dosing Considerations
..................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
.............................................................. 6
4.3 Missed
Dose.....................................